Robert Andtbacka

Company: 7&8 Biopharma

Job title: Chief Medical Officer

Seminars:

Selecting a TLR 7/8 Dual Agonist for Intravenous Delivery & Determining an Appropriate Clinical Dose 12:00 pm

Outlining factors used in selecting a TLR 7/8 dual agonist for intravenous delivery Using immune markers to determine an appropriate clinical dose Harnessing monotherapy and combination therapy clinical responses to guide later-stage trial designRead more

day: Conference Day One

Panel Discussion: Answering the Age-Old Question: Is Systemic Delivery of Innate Agonists Really Viable? 2:30 pm

Join your session leaders in this roundtable as they spark conversions on: Reflecting on the ADU-S100 & SB2-690 trials: what went wrong? What has the data shown us so far on systemic approaches? Given the high toxicity associated with ADCs, is systemic delivery actually that bad relatively? How do you minimize the toxicity that comes…Read more

day: Conference Day One